

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5762658

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ALEXANDRE VASILIEVICH IVACHTCHENKO	08/20/2019
MIKHAIL AIRATOVICH CHAFEEV	08/29/2019
ALEXEY EVGENIEVICH REPIK	06/26/2019
VASILY GENNADIEVICH IGNATIEV	06/19/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC)
<b>Street Address:</b>	BERZARINA STR., 19, BLD. 1
<b>City:</b>	MOSCOW
<b>State/Country:</b>	RUSSIAN FEDERATION
<b>Postal Code:</b>	123154
<b>Name:</b>	ALEXEY EVGENIEVICH REPIK
<b>Street Address:</b>	54 KOTOROSLNAYA NAB., APT. 9
<b>City:</b>	YAROSLAVL
<b>State/Country:</b>	RUSSIAN FEDERATION
<b>Postal Code:</b>	150000
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16340874
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(503)972-9115
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(503) 224-6655
<b>Email:</b>	mandi@khpatent.com
<b>Correspondent Name:</b>	ANTON E. SKAUGSET / KOLISCH HARTWELL, P.C.
<b>Address Line 1:</b>	520 S.W. YAMHILL ST., SUITE 300
<b>Address Line 4:</b>	PORTLAND, OREGON 97204
<b>ATTORNEY DOCKET NUMBER:</b>	ATR302
<b>NAME OF SUBMITTER:</b>	ANTON E. SKAUGSET

<b>SIGNATURE:</b>	/Anton E. Skaugset/
<b>DATE SIGNED:</b>	10/09/2019
<b>Total Attachments: 6</b> source=Executed_Assignment_ATR302#page1.tif source=Executed_Assignment_ATR302#page2.tif source=Executed_Assignment_ATR302#page3.tif source=Executed_Assignment_ATR302#page4.tif source=Executed_Assignment_ATR302#page5.tif source=Executed_Assignment_ATR302#page6.tif	

### ASSIGNMENT

WHEREAS, we, Alexandre Vasilievich IVACHTCHENKO of Hallandale Beach, Florida; Alexey Evgenievich REPIK of Yaroslavl, Russia; Vasily Gennadievich IGNATIEV of Moscow, Russia; and Mikhail Airatovich CHAFEEV of Moscow, Russia, have invented certain improvements in N-{3-[3-CYCLOPROPYL-5-(2-FLUORO-4-IODOPHENYLAMINO)-6,8-DIMETHYL-2,4,7-TRIOXO-3,4,6,7-TETRAHYDRO-2H-PYRIDO[4,3-D]PYRIMIDIN-1-YL]-PHENYL}-CYCLOPROPANECARBOXAMIDE DIMETHYL SULFOXIDE SOLVATE AS AN MEK1/2 INHIBITOR, for which we filed U.S. Patent Application Serial No. 16/340,874 on April 10, 2019; and

WHEREAS, R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC), a Russian company, having its principal place of business in Moscow, Russia; and Alexey Evgenievich REPIK, an individual residing in Yaroslavl, Russia, are desirous of acquiring equal interest therein;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which hereby are acknowledged, we, Alexandre Vasilievich IVACHTCHENKO, Alexey Evgenievich REPIK, Vasily Gennadievich IGNATIEV, and Mikhail Airatovich CHAFEEV, have sold, assigned, and transferred, and do hereby sell, assign, and transfer, to R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK jointly, their successors and assigns, the full and exclusive right to the invention in the United States and its territorial possessions and in all foreign countries, and the entire right, title, and interest in and to any and all Letters Patent that may be granted therefor in the United States and its territorial possessions and in any and all foreign countries, and in and to any and all divisions, continuations, reissues, substitutions, and extensions thereof.

We hereby authorize and request the Patent Office officials in the United States and any and all foreign countries to issue any and all of said Letters Patent, when granted, to R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK, as the assignee

of our entire right, title, and interest in and to the same, for the sole use of R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK, and their successors and assigns.

Further, we hereby covenant and agree to and with R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK, and their successors and assigns, at the time of execution and delivery of these presents, that we are the sole and lawful owners of the entire right, title, and interest in and to the invention and the above-identified patent application, and that the same are unencumbered, and that we have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

Further, we agree that we will communicate to R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK, or their representatives, any facts known to us respecting the invention, and testify in any legal proceedings, sign all lawful papers, execute all divisional, continuation, reissue, substitution, and extension applications, execute all necessary assignment papers to cause any and all of said Letters Patent to be issued to R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK, make all rightful oaths, and generally do everything possible to aid R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK, and their successors and assigns, to obtain and enforce proper protection for the invention in the United States and in any and all foreign countries.

Dated: August 20, 2013

Alex  
ALEXANDRE VASILIEVICH IVACHTCHENKO

Dated: \_\_\_\_\_

\_\_\_\_\_  
ALEXEY EVGENIEVICH REPIK

Dated: \_\_\_\_\_

\_\_\_\_\_  
VASILY GENNADIEVICH IGNATIEV

Dated: 8/29/2019

  
\_\_\_\_\_  
MIKHAIL AIRATOVICH CHAFEEV

### ASSIGNMENT

WHEREAS, we, Alexandre Vasilievich IVACHTCHENKO of Hallandale Beach, Florida; Alexey Evgenievich REPIK of Yaroslavl, Russia; Vasily Gennadievich IGNATIEV of Moscow, Russia; and Mikhail Airatovich CHAFEEV of Moscow, Russia, have invented certain improvements in N-{3-[3-CYCLOPROPYL-5-(2-FLUORO-4-IODOPHENYLAMINO)-6,8-DIMETHYL-2,4,7-TRIOXO-3,4,6,7-TETRAHYDRO-2H-PYRIDO[4,3-D]PYRIMIDIN-1-YL]-PHENYL}-CYCLOPROPANECARBOXAMIDE DIMETHYL SULFOXIDE SOLVATE AS AN MEK1/2 INHIBITOR, for which we filed U.S. Patent Application Serial No. 16/340,874 on April 10, 2019; and

WHEREAS, R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC), a Russian company, having its principal place of business in Moscow, Russia; and Alexey Evgenievich REPIK, an individual residing in Yaroslavl, Russia, are desirous of acquiring equal interest therein;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which hereby are acknowledged, we, Alexandre Vasilievich IVACHTCHENKO, Alexey Evgenievich REPIK, Vasily Gennadievich IGNATIEV, and Mikhail Airatovich CHAFEEV, have sold, assigned, and transferred, and do hereby sell, assign, and transfer, to R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK jointly, their successors and assigns, the full and exclusive right to the invention in the United States and its territorial possessions and in all foreign countries, and the entire right, title, and interest in and to any and all Letters Patent that may be granted therefor in the United States and its territorial possessions and in any and all foreign countries, and in and to any and all divisions, continuations, reissues, substitutions, and extensions thereof.

We hereby authorize and request the Patent Office officials in the United States and any and all foreign countries to issue any and all of said Letters Patent, when granted, to R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK, as the assignee

of our entire right, title, and interest in and to the same, for the sole use of R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK, and their successors and assigns.

Further, we hereby covenant and agree to and with R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK, and their successors and assigns, at the time of execution and delivery of these presents, that we are the sole and lawful owners of the entire right, title, and interest in and to the invention and the above-identified patent application, and that the same are unencumbered, and that we have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

Further, we agree that we will communicate to R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK, or their representatives, any facts known to us respecting the invention, and testify in any legal proceedings, sign all lawful papers, execute all divisional, continuation, reissue, substitution, and extension applications, execute all necessary assignment papers to cause any and all of said Letters Patent to be issued to R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK, make all rightful oaths, and generally do everything possible to aid R-PHARM JOINT STOCK COMPANY (R-PHARM, JSC) and Alexey Evgenievich REPIK, and their successors and assigns, to obtain and enforce proper protection for the invention in the United States and in any and all foreign countries.

Dated: \_\_\_\_\_

\_\_\_\_\_  
ALEXANDRE VASILIEVICH IVACHTCHENKO

Dated: 26.06.2019 \_\_\_\_\_

  
\_\_\_\_\_  
ALEXEY EVGENIEVICH REPIK

Dated: 19.06.2019

VASILY GENNADIEVICH IGNATIEV

Dated: \_\_\_\_\_

MIKHAIL AIRATOVICH CHAFEEV